Accurso F.J. Rowe S.M. Clancy J.P. et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010; 363: 1991-2003 Heijerman H.G.M. McKone E.F. Downey D.G. et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet, London, England)2019 Middleton P.G. Mall M.A. Drevinek P. et al.
